Keywords: icatibant, yields, fast, symptom, improvement, berlin, germany-based

Icatibant yields fast symptom improvement

Article | 23 October 2006

Print This

Berlin, Germany-based drugmaker Jerini AG has reported results from two pivotal Phase III trials of its bradykinin B2 receptor antagonist, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in